Molecular Pathology of Non-Small Cell Lung Cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Surgical Pathology Clinics

• Publication date

  2012-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.path.2012.08.006PMID 26838508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognosis of metastatic carcinoma of the lung in the bevacizumab era: comparison between the major histologic types of lung cancer.

  2012cited by this paper
• Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

  2012cited by this paper
• ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

  2012cited by this paper
• Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

  2012cited by this paper
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Pemetrexed in advanced non-small cell lung cancer

  2011cited by this paper
• Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

  2011cited by this paper
• Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis.

  2011cited by this paper
• Molecular testing of solid tumors.

  2011cited by this paper
• Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

  2011cited by this paper
• Monoclonal antibodies against EGFR in non-small cell lung cancer.

  2011cited by this paper
• EGFR gene status in cytological samples of nonsmall cell lung carcinoma

  2011cited by this paper
• MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

  2011cited by this paper
• Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma.

  2011cited by this paper
• Identification of EGFR mutations in lung sarcomatoid carcinoma

  2011cited by this paper
• Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

  2011cited by this paper
• New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

  2011cited by this paper
• Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.

  2011cited by this paper
• Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens: Utility of an Immunohistochemical Panel Containing TTF-1, Napsin A, p63, and CK5/6

  2011cited by this paper
• Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer.

  2011cited by this paper
• The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma.

  2011cited by this paper
• ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

  2011cited by this paper
• A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer

  2011cited by this paper
• Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer

  2011cited by this paper
• Reduced lung-cancer mortality with low-dose computed tomographic screening.

  2011cited by this paper
• Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

  2011cited by this paper
• ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

  2011cited by this paper
• Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas

  2011cited by this paper
• Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.

  2011cited by this paper
• Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations

  2011cited by this paper
• Prognostic impact of histology on early-stage non-small cell lung cancer.

  2011cited by this paper
• Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing.

  2011cited by this paper
• EGFR mutations and lung cancer.

  2011cited by this paper
• American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

  2011cited by this paper
• Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy

  2011cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

  2011cited by this paper
• Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

  2011cited by this paper
• EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology

  2011cited by this paper
• Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes

  2010cited by this paper
• A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

  2010cited by this paper
• Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

  2010cited by this paper
• The biology and treatment of EML4-ALK non-small cell lung cancer.

  2010cited by this paper
• Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

  2010cited by this paper
• Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cited by this paper
• A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

  2010cited by this paper
• Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

  2010cited by this paper
• Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift.

  2010cited by this paper
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

  2010cited by this paper
• Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas

  2010cited by this paper
• Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

  2010cited by this paper
• Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer

  2010cited by this paper
• Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling.

  2010cited by this paper
• Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Optimal Immunohistochemical Markers For Distinguishing Lung Adenocarcinomas From Squamous Cell Carcinomas in Small Tumor Samples

  2010cited by this paper
• Lung cancer therapeutics that target signaling pathways: an update

  2010cited by this paper
• Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

  2010cited by this paper
• Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas

  2010cited by this paper
• Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• The evolving role of histology in the management of advanced non-small-cell lung cancer.

  2010cited by this paper
• KRAS mutation analysis on cytological specimens of metastatic colo‐rectal cancer

  2010cited by this paper
• Frequency of and variables associated with the EGFR mutation and its subtypes

  2010cited by this paper
• Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations

  2010cited by this paper
• Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

  2010cited by this paper
• Non-small cell lung cancer.

  2010cited by this paper
• Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer.

  2009cited by this paper
• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  2009cited by this paper
• The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

  2009cited by this paper
• EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.

  2009cited by this paper
• Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung

  2009cited by this paper
• MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.

  2009cited by this paper
• The Henry Ford production system: LEAN process redesign improves service in the molecular diagnostic laboratory: a paper from the 2008 William Beaumont hospital symposium on molecular pathology.

  2009cited by this paper
• Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors

  2009cited by this paper
• Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

  2009cited by this paper
• MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

  2009cited by this paper
• Integration of Molecular Profiling into the Lung Cancer Clinic

  2009cited by this paper
• EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti‐EGFR treatment of a rare lung malignancy

  2009cited by this paper
• Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas

  2009cited by this paper
• MET as a target for treatment of chest tumors.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Personalized medicine and inhibition of EGFR signaling in lung cancer.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer

  2008cited by this paper
• A mouse model for EML4-ALK-positive lung cancer

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study

  2008cited by this paper
• Epidermal growth factor-receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung

  2008cited by this paper
• Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

  2008cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

  2008cited by this paper
• MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

  2008cited by this paper

• Precision Targeting of Non-Small Cell Lung Cancer: Identifying Optimal Drug Targets and FDA-Approved Combinations for Enhanced Therapeutic Efficacy

  2023cites this paper
• Smoking Status at Time of Diagnosis Affects the Efficacy of Anti-PD-1/L1 Therapy in Patients With Advanced NSCLC

  2023cites this paper
• Forkhead Box S1 inhibits the progression of lung squamous cell carcinoma cells by mediating Wnt/β-catenin pathway

  2022cites this paper
• The matrix-dependent 3D spheroid model of the migration of non-small cell lung cancer: a step towards a rapid automated screening

  2021cites this paper
• Histopathological effect of pterostilbene as chemoprevention in N-nitroso-tri-chloroethylurea (NTCU)-induced lung squamous cell carcinoma (SCC) mouse model.

  2020cites this paper
• The Correlation between the Intrinsic and Extrinsic Molecular Markers in the Inhibition of the Lungs Carcinogenesis Growth by Mahkota Dewa Polyphenols on Balb/c Mouse

  2020cites this paper
• Molecular and Biological Basis of Lung Cancer-Part I

  2020cites this paper
• Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients

  2019cites this paper
• Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma

  2019cites this paper
• Neoantimycin F, a Streptomyces-Derived Natural Product Induces Mitochondria-Related Apoptotic Death in Human Non-Small Cell Lung Cancer Cells

  2019cites this paper
• The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism

  2019cites this paper
• OTT_A_220698 8139..8149

  2019influential citation
• Histopathological Image Segmentation Using Modified Kernel-Based Fuzzy C-Means and Edge Bridge and Fill Technique

  2019cites this paper
• Lung Cancers and the Roles of Natural Compounds as Potential Chemotherapeutic and Chemopreventive Agents

  2019cites this paper
• Genetic polymorphisms of human cytochrome P450 CYP1A1 in an Egyptian population and tobacco-induced lung cancer

  2017cites this paper
• A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma

  2016cites this paper
• Polyphenol Compounds of Mahkota Dewa (Phaleria macrocarpa [Scheff.] Boerl) Up-regulated Caspase-3 and Apoptosis Index in Balb/c Strain Mice

  2016cites this paper
• The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy

  2016cites this paper
• MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

  2016cites this paper
• Cell death in cancer therapy of lung adenocarcinoma.

  2015influential citation
• Demethoxycurcumin alters gene expression associated with DNA damage, cell cycle and apoptosis in human lung cancer NCI-H460 cells in vitro.

  2015cites this paper
• Proteomic characterization of lung cancer and chronic obstructive pulmonary disease: a bronchoalveolar lavage fluid analysis

  2014cites this paper
• Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases.

  2014cites this paper
• Comparison of inhibitory effect of 17-DMAG nanoparticles and free 17-DMAG in HSP90 gene expression in lung cancer.

  2014cites this paper
• Correlation of transcription of MALAT-1, a novel noncoding RNA, with deregulated expression of tumor suppressor p53 in small DNA tumor virus models.

  2013cites this paper
• Gallotannin regulates apoptosis and COX-2 expression via Akt and p38kinase pathway in human lung cancer cell line, A549

  2012cites this paper
• The Empirical Hierarchical Bayes Approach for Pathway Integration and Gene-Environment Interactions in Genome-Wide Association Studies

  2012cites this paper
• Protein Arginine Methyltransferases (PRMTs): Promising Targets for the Treatment of Pulmonary Disorders

  2012cites this paper
• The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

  2011cites this paper
• Targeted Therapies for Lung Cancer: Clinical Experience and Novel Agents

  2011cites this paper
• Chronic Obstructive Pulmonary Disease-Specific Gene Expression Signatures of Alveolar Macrophages as well as Peripheral Blood Monocytes Overlap and Correlate with Lung Function

  2011cites this paper
• Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma

  2011cites this paper
• CpG Island Methylator Phenotype Involving Chromosome 3p Confers an Increased Risk of Non-small Cell Lung Cancer

  2010cites this paper
• Epidermal Growth Factor Receptor Mutation and p53 Overexpression during the Multistage Progression of Small Adenocarcinoma of the Lung

  2010cites this paper
• Molecular biology of lung cancer: clinical implications.

  2002cites this paper